Skip to content

Study · Non-randomized trial · n = 88 · 1995

3 results

Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems.

Monda JM, Husmann DA

The Journal of urology1 Aug 1995Cited by 45 (Europe PMC)

PMID7609169 (opens in a new tab)DOI10.1097/00005392-199508000-00111 (opens in a new tab)PepBankPUB-07609169
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In primary nocturnal enuresis patients receiving desmopressin acetate, 68% were continent at 6 months.

    In plain wordsIn patients with primary nocturnal enuresis, 68% were continent at 6 months with desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableContinence at 6 months
    Study

    n = 88

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Continent at 6 months
    68%
    desmopressin acetate group, 88 patients

    Source sentences

    Summary
    Similarly, of the 88 patients treated with desmopressin acetate 68% were continent at 6 months but only 10% were continent at 12 months.
    2 context sentences
    Summary · context
    Patients with primary nocturnal enuresis were entered into 4 treatment groups: observation, imipramine, desmopressin acetate or alarm therapy.
    Summary · context
    Patients were weaned from therapy 6 months after inclusion in the study and were evaluated for continence at 3, 6, 9 and 12 months after beginning the study protocol.
  2. 02HumanNon-randomized trialEfficacy outcome

    In primary nocturnal enuresis patients treated with desmopressin acetate, 10% were continent at 12 months after treatment withdrawal.

    In plain wordsIn patients with primary nocturnal enuresis treated with desmopressin, 10% were continent at 12 months after treatment withdrawal.

    Peptide
    Desmopressin
    Outcome
    Not applicableContinence at 12 months
    Study

    n = 88

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Continent at 12 months
    10%
    desmopressin acetate group, 88 patients

    Source sentences

    Summary
    Similarly, of the 88 patients treated with desmopressin acetate 68% were continent at 6 months but only 10% were continent at 12 months.
    2 context sentences
    Summary · context
    Patients were weaned from therapy 6 months after inclusion in the study and were evaluated for continence at 3, 6, 9 and 12 months after beginning the study protocol.
    Summary · context
    Patients with primary nocturnal enuresis were entered into 4 treatment groups: observation, imipramine, desmopressin acetate or alarm therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In primary nocturnal enuresis patients, desmopressin improved continence over observation alone (p < 0.01).

    In plain wordsIn patients with primary nocturnal enuresis, desmopressin improved continence more than observation alone.

    Peptide
    Desmopressin
    Outcome
    IncreaseContinence versus observation
    Study

    n: not reported in source

    Comparator
    Observation alone
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although each form of therapy improved continence over observation alone (p < 0.01), only the bed-wetting alarm system demonstrated persistent effectiveness (p < 0.001).
    2 context sentences
    Summary · context
    Patients with primary nocturnal enuresis were entered into 4 treatment groups: observation, imipramine, desmopressin acetate or alarm therapy.
    Summary · context
    Patients were weaned from therapy 6 months after inclusion in the study and were evaluated for continence at 3, 6, 9 and 12 months after beginning the study protocol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.